BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Sales of Investments
Cash received from selling or redeeming investments.
BioAge Labs, Inc.NASDAQ: BIOA
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments outflow grows to $33.49M
Q1 FY2026 sales of investments was $33.49M, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $93.74M.
Context
- Sales of investments amounted to 669.8% of revenue in FY2025.
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly sales of investments holds near $33.49M or moves back toward the trailing-twelve-month quarterly average of $23.43M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 60.25M USD
- Year-over-year change
- —
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.25M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Sales of Investments vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Sales of investments amounts to 908.7% of revenue for BIOA, versus a peer median of 3.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $366.77M USD | -26.9% | +72.4% | — | |
| LTM Mar 2026 | $249.82M USD | -36.1% | -13.3% | — | |
| LTM Mar 2026 | $100.96M USD | +104.0% | +26.0% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $93.74M USD | — | — | 908.7% |
| LTM Mar 2026 | $82.51M USD | -64.2% | -31.5% | 213.2% | |
| LTM Mar 2026 | $29M USD | +383.3% | — | 69.4% | |
| LTM Mar 2026 | CA$19.23M CAD | +17.0% | -62.5% | 6.2% | |
| LTM Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BIOA) | — | -26.9% | -13.3% | 3.1% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.